Skripsi
EFEK PEMBERIAN STREPTOZOTOCIN TERHADAP KOLESTEROL TOTAL PADA TIKUS MODEL DIABETES MELITUS
Background. Streptozotocin (STZ) is a diabetogenic compound used to induce diabetes mellitus (DM) in animal models. A dose of 45–65 mg/kgBW of STZ triggers the destruction of pancreatic beta cells, resulting in a more stable hyperglycemic condition. Hyperglycemia, as a common feature of DM, leads to metabolic disturbances that cause oxidative stress and dyslipidemia. STZ at a dose of 60 mg/kgBW has been shown to increase lipid profiles in diabetic rat models. This study aims to evaluate the effect of STZ induction on total cholesterol levels in diabetic rat models. Methods. This study is an in vivo experimental study using a posttest with controlled group design. A total of 30 male Wistar rats (Rattus norvegicus) were divided into five groups: STZ-treated groups with doses of 35, 50, 65, and 80 mg/kgBW, and a placebo group. Measurements of body weight, fasting blood glucose, and random blood glucose were performed on days 1, 7, and 14 using a Gluco Dr device. Total cholesterol and triglyceride levels were measured on days 7 and 14 using a spectrophotometer with the CHOD-PAP method (total cholesterol) and the GPO-PAP method (triglycerides). Results. STZ at a dose of 50 mg/kgBW increased total cholesterol levels in rats by 66.7% (>54 mg/dL) on day 7 and triglyceride levels by 16.7% (>145 mg/dL) on day 14. Statistical analysis showed significant differences in total cholesterol and triglyceride levels between the STZ 50 mg/kgBW group and the placebo group (p
| Inventory Code | Barcode | Call Number | Location | Status |
|---|---|---|---|---|
| 2407006881 | T161902 | T1619022024 | Central Library (REFERENCE) | Available but not for loan - Not for Loan |
No other version available